EGFR and non-small cell lung carcinoma: As an initial approach to understanding the mechanisms involved in the differential sensitivity of EGFR-wt and EGFR-mutated NSCLC cells to EGFR-TKIs such as gefitinib and erlotinib, we focused on glucose metabolism, since previous studies suggested that glucose metabolism regulated by EGFR may mediate the therapeutic effects of EGFR-TKIs in EGFR-mutated NSCLC cells [11, 12].